An interventional study of Comparison of eating windows intervention in Type 2 Diabetes Mellitus (T2DM), Hypertension and Obesity and Type 2 Diabetes, sponsored by Federal University of São Paulo. Active, not recruiting at 1 site in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Federal University of São Paulo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil — 35 open to participants now, 44 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Brazil.
Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, this one is the 237th largest by enrollment of the 295 interventional ones that give a count, is one of 23 that started in 2026, is one of 82 with no phase, reaches primary completion later than 21 of the 43 other live ones, and was the 287th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Sao Francisco · Sites in Brazil
Ages 40–80 · Healthy volunteers
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 8 more countries
Ages 18+
AstraZeneca · Sites in Brazil, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 13 more countries
Ages 45+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 7 more countries
Ages 10–18
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 151 · Phase 4 37
First in 2002; this study’s year is marked. 23 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 329 across the 295 interventional studies, 370 across the 22 observational. Of the 239 that completed or were terminated, 116 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 317 have an industry lead sponsor. The 10 most frequent:
Federal University of São Paulo is the lead sponsor of 439 studies on the registry; 23 are open to participants now.
Federal University of São Paulo has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT07463859University of Sao PauloEffects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabetes Mellitus | 2027-01-31 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
| NCT06735859Federal University of São PauloEating Window and Sleep Disorders on Glycemic Control, Cardiovascular Risk, and Weight Loss | 2027-06 |
| NCT07846319epHealthEvaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to offer a quantitative and qualitative nutritional approach, along with educational nutritional guidelines for participants with Non-Communicable Chronic Diseases. The main goals are: 1- Regularization of eating habits and windows; 2- Modulation of biochemical, anthropometric, and cardiovascular parameters; 3- Increase in knowledge about healthy eating. In this way, participants will undergo a complete nutritional assessment, comprising anthropometry, biochemistry, clinical, and dietary evaluations.
The study will be conducted at the Endocrinology and Hypertension Clinic of the São José do Rio Preto Medical School between 2026 and 2027, with the objective of collecting comprehensive data for an in-depth analysis of the participants. Eligible individuals will be randomly assigned to two intervention groups. Participants in the first group will follow a daytime eating window (7:00 a.m. to 7:00 p.m.), while those in the second group will follow a nighttime eating window (12:00 p.m. to 12:00 a.m.). Nutritional consultations will be conducted individually at five assessment points: Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), and Month 18 (follow-up). Each consultation will last approximately one hour per participant, and all participants will receive appointment reminders via phone or WhatsApp.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be instructed to follow the assigned eating window for a period of 6 months. In the daytime eating window, there will also be encouragement for sleep hygiene practices.
Behavioral: Comparison of eating windows intervention
Participants will be instructed to follow the assigned eating window for a period of 6 months.
Behavioral: Comparison of eating windows intervention
Participants will be randomized into two groups to follow either a daytime or nighttime eating window, with normocaloric meal plans based on the Mediterranean diet adapted to Brazilian culture. The first intervention phase will last 6 months, followed by a 3-month washout period during which participants return to their usual eating patterns. After the washout, participants will resume the same eating window for an additional 6 months. A final follow-up assessment will be conducted 3 months post-intervention to evaluate the stability of behavioral changes.
Weight (Kg)
Weight (kg) will be estimated using the Tanita Tetrapolar Bioimpedance Scale with Octaelectrodes BC 601®. Before the consultation, participants will be instructed to attend the meeting wearing light clothing, avoiding heavy meals, fasting from water for 1 hour, and from caffeine for 24 hours prior to the exam. For the measurements, participants will be asked to remove their shoes and empty their bladder. Subsequently, the individual will be asked to step onto the scale. Data will be collected in the morning to mitigate any type of recurring body water fluctuation throughout the day.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Brain and Muscle ARNT-Like 1 (BMAL1)
Analyzed the expression of the gene that works in partnership with CLOCK to activate circadian cycle-related genes during the study.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Circadian Locomotor Output Cycles Kaput (CLOCK)
Analyzed the expression of the gene encoding a key circadian regulatory protein (CLOCK) during the study.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Cryptochrome Circadian Regulator 1 (CRY1)
Analyzed the expression of the gene encoding a key circadian regulatory protein (CRY1) during the study.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Period Circadian Regulator 1 (PER1)
Analyzed the expression of the gene encoding a key circadian regulatory protein (PER1) during the study.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Ambulatory Blood Pressure Monitoring (ABPM)
ABPM will be performed with 24-hour monitoring at five study points to assess circadian blood pressure. Data will include daytime/nighttime averages, dipping patterns, variability, and follow-up changes
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Medications
Medications will be recorded during the nutritional consultation using the anthropometric and clinical evaluation protocols, aiming to mitigate any bias during the intervention.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Physical exercise
The presence or absence of physical exercises was evaluated through conventional qualitative measurement/the survey of the presence or absence of active or sedentary individuals. Patients with levels equal to or greater than 5 trainings sessions per week, with a total duration of 250 min/week, were classified as "active (\>5 sessions)/moderate (=5 sessions)". Patients with levels equal to 3 trainings sessions per week, with a total duration of 150 min/week, were classified as "light". Individuals below this recommendation (\<3 sessions or zero) were considered to be "sedentary".
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Hip Index (HI)
These are statistical corrections of hip circumference, respectively, normalized for height and weight, providing more accurate information regarding the participant's body composition and cardiovascular risk. HI = HC (cm) ∗ Weight (kg) - 0.482 ∗ Height (cm) 0.31
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Neck circumference (cm)
Neck (cm) circumferences will be measured using the 2.0m Sanny® Anthropometric Tape Measure. Neck circumference will be measured by placing the tape around the neck. The ideal neck circumference is up to 37 cm for men and up to 34 cm for women. Measurements below 39.5 cm for men and 36.5 cm for women are considered to indicate a low risk of heart disease or circulatory disorders.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Hip circumference (cm)
Hip circumference will be measured with the 2.0m Sanny® measure using the widest point of the hip or the midpoint of the buttocks
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
HDL cholesterol (mg/dL)
HDL cholesterol will be measured using the Roche cobas c501® equipment. The adequate levels of HDL cholesterol should be higher than 40 mg/dL of blood.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Triglycerides (TG) (mg/dL)
triglycerides (TG) will be measured using the Roche cobas c501® equipment. As for the values of the triglycerides, values below 130 mg/dL are desired.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Plasma glucose (mg/dL)
glucose will be analyzed using Siemens® equipment. For the diagnosis of diabetes, two fasting blood glucose measurements ≥ 126 mg/dL after a minimum of 8 hours of fasting or glycated hemoglobin ≥ 6.5% are considered
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Body fat percentage (%)
body fat percentage (%) will be estimated using the Tanita Tetrapolar Bioimpedance Scale with Octaelectrodes BC 601®. Before the consultation, participants will be instructed to attend the meeting wearing light clothing, avoiding heavy meals, fasting from water for 1 hour, and from caffeine for 24 hours prior to the exam. For the measurements, participants will be asked to remove their shoes and empty their bladder. Subsequently, the individual will be asked to step onto the scale. Data will be collected in the morning to mitigate any type of recurring body water fluctuation throughout the day.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Lean mass (kg)
lean mass (kg) will be estimated using the Tanita Tetrapolar Bioimpedance Scale with Octaelectrodes BC 601®. Before the consultation, participants will be instructed to attend the meeting wearing light clothing, avoiding heavy meals, fasting from water for 1 hour, and from caffeine for 24 hours prior to the exam. For the measurements, participants will be asked to remove their shoes and empty their bladder. Subsequently, the individual will be asked to step onto the scale. Data will be collected in the morning to mitigate any type of recurring body water fluctuation throughout the day.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Sociodemographic assessment:
Sociodemographic assessment: Provides general data such as age, sex, socioeconomic level, race, profession, and others. To classify social classes, the following classifications will be considered: Class A (more than 20 minimum wages); Class B (10 to 20 minimum wages); Class C (four to 10 minimum wages); Class D (two to four minimum wages); and Class E (up to two minimum wages)
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Dietary assessment (habitual food recall)
Dietary assessment (habitual food recall): Analyzes the participant's usual intake, allowing for a thorough evaluation in both quantitative and qualitative aspects, and secondarily in performing calculations/estimates, as well as detecting possible deficiencies/excesses
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Skipping breakfast
The habit of skipping breakfast will be assessed using the metric "yes" or "no." All data mentioned in this session will be evaluated every three months over the 30 months.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is an instrument developed at the University of Pittsburgh, used to identify sleep problems and disorders. It consists of 19 items grouped into seven main components related to sleep: Subjective sleep quality: Assesses overall satisfaction with sleep quality. Sleep latency: Refers to the time required to fall asleep after going to bed. Sleep duration: Measures the total amount of sleep during the night. Sleep efficiency: Calculates the proportion of time spent in bed to the total time of sleep. Sleep disturbances: Investigates the frequency of problems such as apnea, gasping, and nightmares. Use of sleep medication: Identifies the use of substances, such as sleeping pills, to aid sleep. Daytime dysfunction: Assesses the impact of sleep on daily functionality, including energy levels and fatigue. Participants respond to each item based on their experience over the past 30 days, using a scale of 0 to 3.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Blood pressure (BP) (mmHg)
Blood pressure (BP) values will be measured using the Omron Digital Control® equipment, after five to ten minutes of rest, with three readings on the right arm (RA) and left arm (LA), with a one-minute interval between measurements. For participants with BP values \>160/90 mmHg, a five-minute rest period will be conducted before another measurement is taken. For participants with BP values \>200/100 mmHg, where the equipment is unable to measure the pressure, the conventional measurement method using the Nylon Premium Black® sphygmomanometer and Solidor CX® Double Black Stethoscope will be used. Individuals with SBP ≥ 140 mmHg and DBP ≥ 90 mmHg will be considered hypertensive \[5,6\]. Blood pressure and heart rate data will be evaluated every three months over a 30-month period.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Body Shape Index (ABSI)
The calculation of allometric indices will be performed: Body Shape Index (ABSI). These are statistical corrections of waist and hip circumference, respectively, normalized for height and weight, providing more accurate information regarding the participant's body composition and cardiovascular risk. ABSI=WC/BMI2/3×height1/2.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Waist/hip ratio
The waist/hip ratio will also be calculated by dividing the waist circumference (cm) by the hip circumference (cm). Hip circumference will be measured by placing the tape around the widest part of the hip and the midpoint of the buttocks. Desired values are \< 0.85 for women and \< 0.9 for men, indicating low cardiovascular risk. Values above these limits are classified as high risk for cardiovascular diseases.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Waist circumference (cm)
Waist (cm) circumference will be measured using the 2.0m Sanny® Anthropometric Tape Measure. Waist circumference will be measured by placing the tape around the midpoint between the last rib and the hip bone. This point will be marked in advance with a specific pen for anthropometry. Desired waist circumference values are below 80 cm for women and 94 cm for men, indicating "low cardiovascular risk." Values of 80 to 87 cm for women and 94 to 101 cm for men indicate "high cardiovascular risk." Values above 88 cm for women and 102 cm for men indicate "very high cardiovascular risk."
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
BMI (Body Mass Index - Kg/m²)
BMI will be calculated using the formula weight (kg) divided by height squared (m)², with the following categories: Underweight \< 18.5 kg/m²; Normal weight 18.5 - 24.9 kg/m²; Overweight 25.0 - 29.9 kg/m²; Obesity class 1 30.0 - 34.9 kg/m²; Obesity class 2 35.0 - 39.9 kg/m²; Obesity class 3 ≥ 40 kg/m². For participants \> 60 years old, the classification is: Underweight ≤ 22 kg/m²; Normal weight \> 22.0 \< 27.0 kg/m²; Obesity ≥ 27.0 kg/m²
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Height (meters)
Height (meters) will be measured using the Welmy® stadiometer. The participant will be instructed to position themselves with their back against the stadiometer rod, in an upright posture (looking at the horizon and with the chest expanded).
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
LDL cholesterol (mg/dL)
LDL cholesterol will be estimated using the Friedewald Equation (\[LDL\] = (TC - HDL) - (TG/5)). When triglyceride levels are above 400 mg/dL, LDL cholesterol will be calculated using the Roche cobas c501® equipment with Sekisu® reagents \[5,6\]. Adequate levels of LDL cholesterol in healthy individuals should be below 130 mg/dL of blood, and for those at risk, levels should not exceed 70 mg/dL.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Total cholesterol (TC) (mg/dL)
Total cholesterol (TC) will be measured using the Roche cobas c501® equipment. The values of total cholesterol considered to be normal should be below 190 mg/dL, slightly high when they are between 200 and 239 mg/dL, and high when they are above 240 mg/dL.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
HbA1c (%)
HbA1c will be analyzed using Siemens® equipment. For the diagnosis of diabetes, two fasting blood glucose measurements ≥ 126 mg/dL after a minimum of 8 hours of fasting or glycated hemoglobin ≥ 6.5% are considered
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Insulin (µU/mL)
Serum insulin levels will be measured using Siemens® immunoassay equipment. Insulin concentration is a key biomarker for evaluating pancreatic β-cell function and insulin resistance. Reference values: fasting insulin in adults typically ranges from 5-15 µU/mL, with slightly broader ranges observed in children and adolescents (2-25 µU/mL). Elevated fasting insulin levels, in combination with glucose measurements, may indicate impaired glucose metabolism and increased risk for type 2 diabetes.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Creatinine Clearance (24-hour urine, mL/min)
Creatinine clearance will be assessed using 24-hour urine collection and serum creatinine levels, calculated to estimate glomerular filtration rate (GFR). This measure provides an important indicator of renal function and metabolic health. Reference values: adult males (\<40 years) typically show 107-139 mL/min, while adult females (\<40 years) show 87-107 mL/min. Clearance values decline physiologically by approximately 6.5 mL/min per decade of life. Normal 24-hour urine creatinine excretion ranges from 500-2000 mg/day. Reduced clearance values are associated with impaired kidney function and increased cardiovascular risk.
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.
Polysomnography (PSG)
Polysomnography is the gold-standard examination for objective sleep assessment. In the clinical trial, the following parameters will be collected with their respective measurement units: Electroencephalogram (EEG), brain electrical activity recorded in microvolts (µV) to determine sleep stages; Electro-oculogram (EOG), eye movements in microvolts (µV) used to identify REM sleep; Electromyogram (EMG), muscle activity in microvolts (µV) typically from the chin and limbs; Electrocardiogram (ECG), heart rate in beats per minute (bpm); Nasal and oral airflow, measured in liters per minute (L/min); Thoracic and abdominal movements, respiratory effort in centimeters of displacement (cm) or relative sensor units; Pulse oximetry, peripheral oxygen saturation in percentage (%SpO₂); Apnea-Hypopnea Index (AHI), number of events per hour of sleep (events/h); Total Sleep Time (TST), minutes (min); Sleep latency, minutes (min); Sleep efficiency, percentage (%) calculated as TST/total time in bed ×
Time frame: 5 assessment points - Month 0 (baseline), Month 6 (end of first intervention phase), Month 9 (end of washout), Month 15 (end of second intervention phase), FOLLOW-UP Month 18.]
Plan to share: Yes — The study data will be collected, managed, and stored using the REDCap 14.0.9 electronic data capture tools hosted at REDCap - FUNFARME/FAMERP and the database of the Federal University of São Paulo (UNIFESP) - Baixada Santista Campus. After scientific publications, the data will be made available to the scientific community upon request to the researchers responsible for the study.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: The data will only be available 12 months after publication and will be provided upon formal request to the principal researcher, in accordance with the guidelines of non-paid international journal publishers (subscription option).
Access criteria: After this period, the data will be provided upon formal request to the principal researcher for up to 6 months. A link will be created with direct access to the data, or upon demand and request, the data will be provided directly to the interested researchers.
Data sharing details ↗ · drive.google.com
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 17 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federal University of São Paulo →